Advertisement
Advertisement
U.S. Markets open in 2 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.17-0.06 (-0.19%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close32.23
Open32.04
Bid0.00 x 1100
Ask0.00 x 900
Day's Range31.96 - 32.40
52 Week Range23.67 - 43.94
Volume72,749
Avg. Volume204,778
Market Cap4.79B
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.39
  • Zacks

    Hutchison China MediTech (HCM) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Hutchison China MediTech (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • Insider Monkey

    Do Hedge Funds Love HUTCHMED (China) Limited (HCM)?

    The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • GlobeNewswire

    HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 28, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) announces that new and updated clinical data from several ongoing combination studies of surufatinib (SULANDA® in China) or fruquintinib (ELUNATE® in China) with PD-1 inhibitors were presented at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting which has been taking place on September 25-29, 2021. SURUFATINIB Title:A phase I

Advertisement
Advertisement